Jasmina Kalabic

1.7k total citations
68 papers, 563 citations indexed

About

Jasmina Kalabic is a scholar working on Genetics, Epidemiology and Hematology. According to data from OpenAlex, Jasmina Kalabic has authored 68 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 30 papers in Epidemiology and 19 papers in Hematology. Recurrent topics in Jasmina Kalabic's work include Inflammatory Bowel Disease (39 papers), Microscopic Colitis (26 papers) and Autoimmune and Inflammatory Disorders Research (19 papers). Jasmina Kalabic is often cited by papers focused on Inflammatory Bowel Disease (39 papers), Microscopic Colitis (26 papers) and Autoimmune and Inflammatory Disorders Research (19 papers). Jasmina Kalabic collaborates with scholars based in United States, Germany and Canada. Jasmina Kalabic's co-authors include H. Küpper, Sandra Goss, Gerd Horneff, Remo Panaccione, Aileen L. Pangan, Geert D’Haens, J. Anderson, Gurjit S. Kaeley, Edward V. Loftus and Rubén Burgos‐Vargas and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

Jasmina Kalabic

56 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jasmina Kalabic United States	13	243	207	179	177	150	68	563
Graciela Espada Argentina	11	55 0.2×	236 1.1×	169 0.9×	127 0.7×	332 2.2×	32	624
Polyxeni Pratsidou‐Gertsi Greece	14	56 0.2×	309 1.5×	68 0.4×	241 1.4×	326 2.2×	35	603
Claudia Saad‐Magalhães Brazil	10	48 0.2×	213 1.0×	72 0.4×	60 0.3×	224 1.5×	22	396
K. Mazodier France	12	47 0.2×	307 1.5×	72 0.4×	275 1.6×	100 0.7×	37	743
Dana Němcová Czechia	13	32 0.1×	180 0.9×	63 0.4×	80 0.5×	120 0.8×	37	478
Ryoki Hara Japan	14	30 0.1×	269 1.3×	82 0.5×	167 0.9×	175 1.2×	44	555
Cássia Maria Passarelli Lupoli Barbosa Brazil	14	31 0.1×	111 0.5×	63 0.4×	100 0.6×	234 1.6×	28	434
Susan Shenoi United States	15	35 0.1×	496 2.4×	59 0.3×	190 1.1×	101 0.7×	41	702
Adriaan A. van Bodegraven Netherlands	11	291 1.2×	32 0.2×	208 1.2×	124 0.7×	39 0.3×	29	554
Corinne Antoine France	10	160 0.7×	162 0.8×	226 1.3×	250 1.4×	45 0.3×	17	695

Countries citing papers authored by Jasmina Kalabic

Since Specialization

Citations

This map shows the geographic impact of Jasmina Kalabic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmina Kalabic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmina Kalabic more than expected).

Fields of papers citing papers by Jasmina Kalabic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasmina Kalabic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmina Kalabic. The network helps show where Jasmina Kalabic may publish in the future.

Co-authorship network of co-authors of Jasmina Kalabic

This figure shows the co-authorship network connecting the top 25 collaborators of Jasmina Kalabic. A scholar is included among the top collaborators of Jasmina Kalabic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmina Kalabic. Jasmina Kalabic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reinisch, Walter, Edward V. Loftus, Stefan Schreiber, et al.. (2025). Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. Journal of Crohn s and Colitis. 19(4).

Panaccione, Remo, Édouard Louis, Jean–Frédéric Colombel, et al.. (2025). Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. Journal of Crohn s and Colitis. 19(1). 5 indexed citations

Panaccione, Remo, Marc Ferrante, Iris Dotan, et al.. (2025). Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment. Clinical Gastroenterology and Hepatology. 23(11). 2012–2022.e6. 3 indexed citations

Torres, Joana, Julián Panés, Corey A. Siegel, et al.. (2025). Symptom Resolution and Meaningful Improvement in Quality of Life With Risankizumab in Patients With Ulcerative Colitis: Post Hoc Analysis of the Randomized INSPIRE and COMMAND Studies. The American Journal of Gastroenterology. 120(8). 1820–1828.

Cestari, Tânia Ferreira, Cacilda da Silva Souza, Luna Azulay‐Abulafia, et al.. (2024). Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. 100(2). 260–271.

Panaccione, Remo, Édouard Louis, Jean‐Frédéric Colombel, et al.. (2024). P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies. Journal of Crohn s and Colitis. 18(Supplement_1). i1146–i1148. 1 indexed citations

Feagan, Brian G., Remo Panaccione, Edward V. Loftus, et al.. (2024). Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease. SHILAP Revista de lepidopterología. 4(4). 100603–100603. 2 indexed citations

Feagan, Brian G., Jean–Frédéric Colombel, Remo Panaccione, et al.. (2024). Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease. SHILAP Revista de lepidopterología. 4(1). 100544–100544. 1 indexed citations

Schreiber, Stefan, Remo Panaccione, Gareth Parkes, et al.. (2024). 984 RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND STUDY. Gastroenterology. 166(5). S–238. 1 indexed citations

10.

D’Cunha, Ronilda, et al.. (2024). Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease. Clinical Pharmacokinetics. 64(1). 143–154. 1 indexed citations

11.

Ferrante, Marc, Peter M. Irving, María T. Abreu, et al.. (2023). Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial. Journal of Crohn s and Colitis. 18(3). 416–423. 5 indexed citations

12.

Colombel, Jean‐Frédéric, Stefan Schreiber, Geert D’Haens, et al.. (2023). Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. Journal of Crohn s and Colitis. 18(6). 818–827. 6 indexed citations

13.

Pang, Yinuo, Ronilda D’Cunha, Afroz S. Mohammad, et al.. (2023). Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease. Clinical Therapeutics. 46(1). 30–39. 5 indexed citations

14.

Loftus, Edward V., Jenny Griffith, Ezequiel Neimark, et al.. (2023). Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease. Advances in Therapy. 40(5). 2311–2325. 9 indexed citations

15.

Bossuyt, Peter, Francesca Bresso, Marla C. Dubinsky, et al.. (2022). OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Journal of Crohn s and Colitis. 16(Supplement_1). i048–i048. 6 indexed citations

16.

Chen, Baili, Xiang Gao, Jie Zhong, et al.. (2020). Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn’s disease: results from a randomized trial. Therapeutic Advances in Gastroenterology. 13. 3974127824–3974127824. 27 indexed citations

17.

Ferrante, Marc, Julián Panés, Filip Baert, et al.. (2019). OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study. A64.1–A64. 1 indexed citations

18.

Kaeley, Gurjit S., Daryl MacCarter, Shufang Liu, et al.. (2018). Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial. Rheumatology and Therapy. 5(1). 123–134. 8 indexed citations

19.

D’Haens, Geert, Walter Reinisch, Remo Panaccione, et al.. (2018). Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry. The American Journal of Gastroenterology. 113(6). 872–882. 55 indexed citations

20.

Kaeley, Gurjit S., M. Nishio, Daryl MacCarter, et al.. (2016). Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. Arthritis & Rheumatology. 68(11). 2584–2592. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact